Methodological considerations in meta-analytic evaluation of cangrelor in critically ill patients: a response to Bottussi et al. - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Addressing Methodological Issues in the Meta-Analysis of Cangrelor for Critically Ill Patients: A Reply to Bottussi et al.

  • By

  • Hendrianus Hendrianus

  • Sang Yeub Lee

  • Jun Hwan Cho

  • Jinhwan Jo

  • Sang-Wook Kim

  • Young-Hoon Jeong

  • May 4, 2026

Share

Objective:

To clarify methodological aspects of the meta-analysis evaluating cangrelor's efficacy and safety in critically ill patients undergoing PCI.

Approach:
    Key Findings:
    • Heterogeneity in dosing and timing does not undermine the validity of pooled estimates.
    • Crude event data was used for primary analysis, consistent with meta-analysis standards.
    • Exploratory analyses were clearly distinguished and did not influence primary conclusions.
    Interpretation:

    The methodological approach was appropriate given the limited and heterogeneous evidence in critically ill populations, ensuring transparent reporting and avoiding overinterpretation.

    Limitations:
    • Limited number of randomized controlled trials in the field.
    • Inconsistent reporting of dosing and timing across studies.
    • Exploratory analyses based on small sample sizes.
    Conclusion:

    The authors maintain that their methodological approach aligns with established standards for meta-analysis, emphasizing the importance of transparency and cautious interpretation of findings.

Original Source(s)

Methodological considerations in meta-analytic evaluation of cangrelor in critically ill patients: a response to Bottussi et al.

  • by Hendrianus Hendrianus, Sang Yeub Lee, Jun Hwan Cho, Jinhwan Jo, Sang-Wook Kim, Young-Hoon Jeong

  • May 4, 2026

Related Content

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.

Dr. Jordan Strom on ASE 2026 Scientific Sessions: AI, Access, and the Future of Echocardiography

As ASE convenes its 37th Scientific Sessions near Denver, the meeting will spotlight echocardiographic AI and big data, contrast-enhanced ultrasound, evolving guidelines, the Feigenbaum Lecture, and the future of the sonographer workforce.